Search

Search Constraints

You searched for: Author/Creator Mehra, Ranee

Search Results

33. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Issue 10167 (12th January 2019)

34. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). Issue 2 (10th January 2022)

35. Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer. Issue 11 (November 2015)

36. Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer. Issue 11 (November 2015)

37. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. (April 2019)

38. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. (14th May 2020)

40. Regionalization of Head and Neck Oncology Tumor Boards: Perspectives of Collaborating Physicians. Issue 1 (28th February 2023)